Onco-Innovations Advances ONC010 Manufacturing Process Development, a Key Step Toward IND-Enabling Studies

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This milestone advances the company’s chemistry, manufacturing, and controls (CMC) strategy as it moves toward IND-enabling studies and planning for first-in-human clinical evaluation.

The company stated that the program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness, and future clinical supply requirements. This development underscores Onco-Innovations’ commitment to advancing its oncology pipeline and addressing the critical need for effective cancer treatments.

The announcement is significant because it demonstrates tangible progress in the drug development pathway. For a biotech company, moving from early-stage research to process development and scale-up is a crucial step that de-risks the manufacturing process and prepares the candidate for regulatory submissions. Investors and stakeholders should view this as a positive signal that Onco-Innovations is methodically progressing toward clinical trials, potentially enhancing the company’s valuation and attracting further interest from partners or investors.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit https://oncoinnovations.com/.

The full press release can be viewed at https://nnw.fm/kfFWv.